Oxford BioDynamics PLC Publication of 2020 Annual Report and AGM date (0774Q)
February 23 2021 - 8:36AM
UK Regulatory
TIDMOBD
RNS Number : 0774Q
Oxford BioDynamics PLC
23 February 2021
23 February 2021
Oxford Biodynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
PUBLICATION OF 2020 ANNUAL REPORT
Oxford BioDynamics Plc (AIM: OBD), a biotechnology company
developing precision medicine tests for personalized healthcare
based on the EpiSwitch (R) 3D genomics platform, today announces
that copies of its annual report and accounts for the year ended 30
September 2020 (incorporating the Notice of Annual General Meeting)
("Annual Report") have been posted to shareholders. An electronic
copy of the Annual Report will be available on its website at
investors.oxfordbiodynamics.com.
As stated in the recent Full Year results announcement, the
Company's Annual General Meeting will be held at Oxford Works,
Building 4650 Kingsgate, Oxford Business Park, Oxford, OX4 2SU on
24 March 2021 at 12.00pm.
-ENDS-
For further details please contact:
Oxford BioDynamics Plc Tel: +44 (0)1865 518910
Jon Burrows, CEO
Paul Stockdale, CFO
Shore Capital - Nominated Adviser and Tel: +44 (0)20 7408 4090
Broker
Advisory: Edward Mansfield / John More
Broking: Fiona Conroy
Instinctif Partners Tel: +44 (0)20 7457 2020
Melanie Toyne-Sewell / Agnes Stephens OxfordBioDynamics@instinctif.com
/ Katie Duffell / Nathan Billis
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology
company, advancing personalized healthcare by developing and
commercializing precision medicine tests for life-changing
diseases.
The Company has developed a proprietary 3D genomic biomarker
platform, EpiSwitch(R), which can build molecular diagnostic
classifiers for prediction of response to therapy, patient
prognosis, disease diagnosis and subtyping, and residual disease
monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships
with big pharma and leading institutions including Pfizer, EMD
Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts
General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio,
including biomarker arrays, molecular diagnostic tests,
bioinformatic tools for 3D genomics and an expertly curated 3D
genome knowledgebase comprising hundreds of millions of data points
from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on the London
Stock Exchange's AIM market. It also has a commercial team in the
US and a reference laboratory in Penang, Malaysia.
For more information, please visit the Company's website,
www.oxfordbiodynamics.com , or follow on Twitter or LinkedIn .
About EpiSwitch(R)
The 3D configuration of the genome plays a crucial role in gene
regulation. By mapping this architecture and identifying abnormal
configurations, EpiSwitch(R) can be used to diagnose patients or
determine how individuals might respond to a disease or
treatment.
Built on over 10 years of research, EpiSwitch(R) is Oxford
Biodynamics' award-winning, proprietary platform that enables
screening, evaluation, validation and monitoring of 3D genomic
biomarkers. The technology is fully developed, based on testing of
over 10,000 samples in 30 disease areas, and reduced to
practice.
In addition to stratifying patients with respect to anticipated
clinical outcome, EpiSwitch (R) data offer insights into systems
biology and the physiological manifestation of disease that are
beyond the scope of other molecular modalities. The technology has
performed well in academic medical research settings and has been
validated through its integration in biomarker discovery and
clinical development with big pharma.
Oxford BioDynamics is leveraging its leading technology to
develop a pipeline of tests in a wide range of indications, such as
COVID-19 severity, immuno-oncology, neurodegenerative and
autoimmune diseases.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSFLFVVFLIVFIL
(END) Dow Jones Newswires
February 23, 2021 08:36 ET (13:36 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024